Revascularization Strategy in Myocardial Infarction with Multivessel Disease.
NSTEMI
STEMI
acute coronary syndrome
multivessel disease
revascularization
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
received:
27
01
2024
revised:
18
03
2024
accepted:
22
03
2024
medline:
13
4
2024
pubmed:
13
4
2024
entrez:
13
4
2024
Statut:
epublish
Résumé
The proportion of patients with multivessel coronary artery disease in individuals experiencing acute coronary syndrome (ACS) varies based on age and ACS subtype. In patients with ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock, the prognostic benefit of complete revascularization has been demonstrated by several randomized trials and meta-analyses, leading to a strong guideline recommendation. However, similar data are lacking for ACS without ST-segment elevation (NSTE-ACS). Non-randomized data suggesting a benefit from complete revascularization in non-ST-segment elevation myocardial infarction (NSTEMI) are prone to selection bias and should be interpreted with caution. A series of large randomized controlled trials have been initiated recently to address these open questions.
Identifiants
pubmed: 38610683
pii: jcm13071918
doi: 10.3390/jcm13071918
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng